Skip to content

The Construction of Objective Diagnosis and Early Efficacy Prediction Platform for Major Depressive Disorder Based on Imaging Proteomics

The Construction of Objective Diagnosis and Early Efficacy Prediction Platform for Major Depressive Disorder Based on Imaging Proteomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032037
Enrollment
Unknown
Registered
2020-04-18
Start date
2020-04-20
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression and other common mental disorder

Interventions

Case group versus normal group:Nil

Sponsors

Department of Psychosomatics and Psychiatry, Southeast University Affiliated Zhongda Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: MDD inclusion criteria: 1. Patients who meet the diagnostic criteria of MDD in DSM-IV; 2. Patients with Hamilton Depression Scale 17 item (HAMD-17) score = 17; 3. Patients aged 18-60; 4. Patients with no history of electroconvulsive therapy; 5. Right handed patients. Normal control (HC) inclusion criteria: 1. The sex, age and education level of the patients match with those of the patients. The HAMD-17 score is less than 8 (and the "depression" score is 0); 2. Subjects with no history of severe gravity, brain and kidney diseases, alcohol and drug abuse, and family history of mental diseases; 3. Patients without pacemaker or metal material can be examined by MRI. T2 weighted MRI does not show cerebral infarction or other vascular damage; 4. Right handed objects.

Exclusion criteria

Exclusion criteria: MDD exclusion criteria: 1. Patients with serious suicidal tendency; 2. Patients who had taken mood stabilizers, antipsychotics or any antidepressants within 2 weeks before admission; 3. Patients with previous history of other mental diseases; 4. Patients with obvious abnormality in laboratory and auxiliary examination; 5. Patients who do not cooperate with the examination or fail to complete the examination due to the disturbance of consciousness or vision, hearing, language expression and understanding; 6. Patients with primary brain tumor, brain metastasis, brain injury, multiple sclerosis or severe body disease (including severe cardiopulmonary, hepatorenal insufficiency, shock, malignant tumor or hematopathy, autoimmune disease); 7. Patients with cerebral infarction or other vascular injury on T2 weighted MRI; 8. Patients with pacemakers or metal materials in the body that cannot be examined by MRI.

Design outcomes

Primary

MeasureTime frame
MRI;Peripheral blood protein index;Clinical scale;

Countries

China

Contacts

Public ContactYuan Yonggui

Southeast University Affiliated Zhongda Hospital

yygylh2000@sina.com+86 25-83285124

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026